Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2010
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Fusimabs platform is based on inclonal technology developed by Professor Itai Benhar at the University of Tel-Aviv. It is designed to enable the efficient expression and folding of full-length antibodies in bacterial culture. Fusimab is leveraging its platform for development of bi-specific antibodies and antibody toxin fusion proteins for cancer treatment.The technology may offer a way to speed up drug discovery and manufacturing.
Q&A
- What is Fusimab's primary focus?
- Fusimab focuses on cancer drug discovery using bi-specific antibodies and antibody toxin fusion proteins for cancer treatment.
- When was Fusimab founded?
- Fusimab was founded in January 2010.
- What is the current status of Fusimab?
- Fusimab is currently inactive, as of November 2014.
- Where is Fusimab headquartered?
- Fusimab is headquartered in Tel Aviv-Yafo, Center District, Israel.
- What technology is Fusimab's platform based on?
- Fusimab's platform is based on inclonal technology developed by Professor Itai Benhar at the University of Tel-Aviv, designed for efficient expression and folding of full-length antibodies in bacterial culture.
- What is Fusimab's primary sector classification?
- Fusimab's primary sector is Health Tech & Life Sciences.
- What is Fusimab's current funding stage?
- Fusimab is in the Pre-Funding stage.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Tags
antibodiespharmaceuticalsbiotechnologycancerbacteriapharma-companiestreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2010-1 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Nov 2014 |